Does the duration of exposure to everolimus influence the occurrence of chronic lung allograft dysfunction?

Landoas A, Perrier Q, Falque L et al. · 2026 · Transplant Immunology · Atlas ID LANDOAS2026

What this study shows

In lung transplant recipients, later introduction of everolimus and a greater number of treatment interruptions were both risk factors for chronic lung allograft dysfunction — suggesting early, uninterrupted mTOR inhibition is protective.

Abstract

ShowHide

Everolimus has been incorporated into the immunosuppressive management of lung transplant patients. Due to its anti-proliferative properties it is being studied in the context of chronic lung allograft dysfunction (CLAD). A retrospective single-centre observational study of lung transplant patients between January 2000 and August 2021 treated with everolimus during follow-up. The timing of everolimus introduction was identified as a risk factor for CLAD (OR 1.069, 95% CI 1.017-1.123), as was the number of everolimus discontinuations (OR 12.660, 95% CI 1.025-156.329).

Read the full abstract →

At a glance

Evidence type	H Human study Marked H because it is direct evidence from a human clinical trial or human cohort; the code names the kind of study, not its quality -- a small, well-run trial is still H.
Study type	3 - Human Observational
Model system	Human (single-centre retrospective observational)
Journal	Transplant Immunology
Year	2026
Peer reviewed	Yes
Record last updated	2026-08-22
Source	DOI 10.1016/j.trim.2026.102436

Extracted findings

Intervention	Everolimus
Target	mTOR
Model	Human
Effect	Early introduction and fewer interruptions associated with lower CLAD risk; lung function stability maintained

Cite this paper

ShowHide

Landoas, A., et al. (2026). Does the duration of exposure to everolimus influence the occurrence of chronic lung allograft dysfunction?. Transplant Immunology. https://doi.org/10.1016/j.trim.2026.102436

@article{LANDOAS2026,
  author       = {Landoas, A. and Perrier, Q. and Falque, L. and others},
  title        = {{Does the duration of exposure to everolimus influence the occurrence of chronic lung allograft dysfunction?}},
  journal      = {Transplant Immunology},
  year         = {2026},
  doi          = {10.1016/j.trim.2026.102436},
}

Cite this Atlas record

The record is the Atlas's own work — the evidence label, the extracted findings and the links. It is cited as part of the dataset, not as the paper.

Barton, O. (2026). Oliver's mTOR Atlas (record LANDOAS2026) [Data set]. https://mtor-atlas.org/study/LANDOAS2026/ · Dataset DOI 10.5281/zenodo.22059963

@misc{atlas_LANDOAS2026,
  author       = {Barton, Oliver},
  title        = {{Oliver's mTOR Atlas}, record LANDOAS2026},
  howpublished = {Data set},
  year         = {2026},
  url          = {https://mtor-atlas.org/study/LANDOAS2026/},
  doi          = {10.5281/zenodo.22059963}
}